Trial reportAddiction (Abingdon, England)2026
Titration of nicotine intake in smokers switching to reduced nicotine content cigarettes with access to alternative nicotine systems: Secondary analysis of a randomized clinical trial.
Trial report in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03272685 (Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace Part of "Evaluating New Nicotine Standards for Cigarettes"), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace Part of "Evaluating New Nicotine Standards for Cigarettes"
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsMandated reduction of the nicotine content of cigarettes to reduce addictiveness to minimal levels has the potential to substantially reduce combusted cigarette use and promote public health. This paper examined the hypothesis that when people who smoke cigarettes are switched to very low nicotine content (VLNC) cigarettes and provided with access to non-combusted alternative nicotine delivery systems (ANDS), they will titrate nicotine to maintain baseline levels of nicotine intake with the use of ANDS.
designThis is a secondary analysis of a recently published randomized clinical trial. Clinical trial number NCT03272685.
settingMulticenter clinical trial conducted in the United States.
participants438 individuals who smoked 5 to 40 cigarettes per day, mean age 44 (range 20-73).
interventionSmokers were randomized 1:1 for 12 weeks of smoking Spectrum brand research cigarettes containing VLNC (0.4 mg nicotine/g tobacco) or normal nicotine content (15.8 mg nicotine/g, NNC). Participants purchased tobacco products from an experimental marketplace containing non-combusted ANDS, including electronic cigarettes, nicotine replacement medications and oral nicotine products. MEASUREMENTS: Measures taken at baseline, 4, 8 and 12 weeks included cigarettes smoked per day (CPD) and measures of ANDS use, assessed using past 3-day daily diary data, which would roughly account for nicotine intake as measured by urine total nicotine equivalents (TNE). Based on self-report and biomarker data at weeks 4, 8 and 12, we characterized three product-using groups of participants as cigarette-only users, ANDS-only users and dual users. Nicotine titration was assessed as the ratio of urine TNE at various research cigarette study weeks compared with baseline (smoking their own cigarettes). Combusted product abstinence was examined using expired carbon monoxide (CO) and adherence to smoking VLNC by urine anatabine.
findingsMedian titration at 12 weeks in cigarette-only participants was 0.84 (interquartile range 0.68-1.18) in the NNC group and 0.05 (0.01-0.12) in the VLNC group. Median titration at 12 weeks in ANDS-only participants was 0.81 (0.69-1.16) in the NNC group and 0.89 (0.49-1.58) in the VLNC group. Median titration at 12 weeks in dual use participants was 1.0 (0.78-1.29) in the NNC group and 0.91 (0.61-1.25) in the VLNC group.
conclusionsMost adults who smoke, when switched to very low nicotine content cigarettes, will use available alternative nicotine delivery systems (ANDS) to supplement their intake of nicotine. Provision of ANDS appears to be associated with a high degree of nicotine titration. Making less harmful ANDS widely available may make a mandated nicotine reduction intervention more acceptable to people who smoke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.